Diet and gut bacteria in early-stage triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how your diet and the natural bacteria in your gut (microbiome) may affect how well chemotherapy and immunotherapy work for early-stage triple-negative breast cancer. By participating, you may help doctors understand if certain gut bacteria can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with early-stage triple-negative breast cancer (a type of breast cancer that does not have receptors for estrogen, progesterone, or HER2) with a tumor size of at least 1 cm.
- You are planning to receive chemotherapy before surgery, with or without immunotherapy (treatment that helps your immune system fight cancer).
- You have not had any prior treatment for this breast cancer (such as surgery, radiation, or chemotherapy).
- You have not taken antibiotics (oral or IV) within the past 14 days.
- The cancer has not spread to other parts of the body (no distant metastases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a treatment that targets your gut bacteria (microbiome) can help fight triple-negative breast cancer before surgery. It is for people with newly diagnosed, untreated triple-negative breast cancer that has not spread far.
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
This study looks at how bacteria in your gut might affect the way your body responds to immunotherapy for triple-negative breast cancer. It focuses on women who are overweight or obese and are about to start treatment with pembrolizumab before surgery.
This study tests a lifestyle program (diet, exercise, and support) for women with triple-negative breast cancer who are getting chemotherapy plus immunotherapy before surgery. The goal is to see if healthy habits can help during treatment.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Triple Negative Breast Cancer (TNBC), Early Setting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.